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The essence of healthy existence for every living being is homeostasis within itself and the surrounding environment.  
Sadly, the human being, despite being at the highest echelons 
of the animal kingdom, is the only living organism who 
continuously defies this ideology resulting in the calamitous 
state of affairs we are experiencing both in our environment 
and in our personal health, both physical and psychological.
Vaginal ailments, even though usually not so devastating, 
are a clear example of how loss of ecological balance can affect 
our quality of life.  The most common of these is vaginitis, and 
more specifically, bacterial vaginosis.
Homeostasis in the post-pubertal human vagina is 
maintained by the colonization of commensal bacteria, mainly 
hydrogen peroxide-producing lactobacilli1.  other bacteria 
are also present, namely streptococcal species, gram-negative 
bacteria and other anaerobic species, including Gardnerella 
vaginalis. Candida albicans is also present in 10 to 25% of 
asymptomatic women2.
estrogen increases the production of glycogen in vaginal 
epithelial cells and its metabolism by the lactobacilli to lactic 
acid.  This renders the vaginal ecosystem mildly acidic (pH 
3.8-4.5) and inhibits the adherence of bacteria to vaginal cells; 
the hydrogen peroxide which is produced by the lactobacilli 
inhibits the growth of bacteria and has also been found to kill 
HIV in vitro2. This mutualism between lactobacilli and vaginal 
epithelium, together with innate and acquired immunity, 
protects the vagina from colonisation by pathogenic bacteria, 
thus preventing ascending or systemic infection3.  
The chAlleNGeS TO hOmeOSTASIS 
IN The VAGINAl ecOSySTem 
The most common organisms causing vaginitis are bacteria, 
fungi and protozoa.  Bacterial vaginosis is not caused by one 
agent4, as is commonly believed but is rather a polymicrobial 
syndrome usually caused by Gardnerella vaginalis, Mobilincus, 
Bacteroides saprophytes and Mycobacterium Hominus; 
Chlamydia trachomatis and Neisseria gonorrhoea are less 
commonly implicated with bacterial vaginosis. Fungal vaginitis 
is usually caused by Candida albicans. The epidemiology varies 
according to the geographical location - bacterial vaginosis is 
the most common vaginal infection followed by vulvo-vaginal 
candidiasis in the uS; in europe however, the fungal form is the 
most prevalent1.
Bacterial and fungal vaginosis usually occur following the 
exposure to an external agent that alters the vaginal homeostasis 
either by altering the pH or by disturbing the vaginal commensal 
flora.  This could include biological factors like pregnancy 
and menopause or external agents such as vaginal douches, 
chemotherapy (direct inhibition or cell lysis5), sexual intercourse 
(multiple partners) and contraception (IuD). trichomoniasis, 
on the other hand, is a sexually transmitted disease caused by 
the protozoan Trichomonas vaginalis.  Vaginosis is easily curable 
with adequate treatments; however all types can be associated 
with recurrent relapses and adverse outcomes, including 
increased risk of HIV or other forms of upper genital infections 
including pelvic inflammatory disease, premature rupture of 
membranes or abortion1,2.
Despite there being a few lactobacillus species constituting 
the vaginal flora, there are various species- and strain-specific 
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differences which account for the wide variability in their ability 
to maintain the stability of the vaginal ecosystem.  Thus, the 
vaginal immunity is one of the factors - apart from the effect 
of endocrinal changes on vaginal physiology, and external 
challenges - in determining both the liability to infection and 
recurrence, as well as the propensity to respond to treatment3.
Diagnosis hinges on the symptomatology described by the 
patient and the naked eye examination of the vaginal discharge. 
The clinical findings can be very similar especially in the 
bacterial and fungal cases which can render diagnosis difficult. 
Microscopical assessment of the discharge is the mainstay of 
diagnosis; unfortunately it is usually resorted to on therapeutic 
failure of the usual repeated courses of empirical therapy; this 
not only leads to a financial and social burden resulting in non-
compliance on the part of the patients but also contributes to the 
overall emergence of resistance1.
The hallmark of the management of vaginitis rests on the 
triad of prevention, education and antimicrobial treatment, all 
of which lie in the remit of the general practitioner.  education 
so far is mostly carried out through face-to-face interventions 
when the patient turns up for treatment of one or more of the 
unpleasant symptoms, or for the insertion of a contraceptive 
device.  The success of prevention is directly proportional to how 
much the educational messages manage to get driven home and 
how much the patient truly comprehends and appreciates their 
importance especially considering the embarrassment associated 
with such disturbances.
Antimicrobial treatment comes mostly in the form of topical 
agents - creams or pessaries - or oral medication.  Creams or 
pessaries can deliver either one antimicrobial agent or contain 
a synergistic combination of two or more active ingredients to 
increase the likelihood of remission and decrease the risk of 
recurrence.
unfortunately, recurrence of vaginal infections is common.  
In most cases this is the result of wrong diagnosis, self-treatment 
with over-the-counter medication, poor compliance to 
treatment by the female, failure to treat the male partner, 
resistance to treatment and/or non-adherence to the 
preventive measures advised.  The rest of the recurrences 
occur due to an inherent predisposition of the female, either 
as a result of a particular physiological state e.g. pregnancy 
and menopause, the presence of an IuD, insufficient 
numbers of peroxide-producing vaginal lactobacilli or 
altered host immune response3.
The best way to avoid this state of affairs is to take a 
structured and systematic approach to the management 
of vaginitis. A good history from the patient regarding 
symptomatology, past medical history and sexual/gynae 
history is an important start. This should be ideally followed 
by pelvic examination including determination of vaginal 
pH, visual assessment and microscopic evaluation of the 
discharge2. It is only through correct diagnosis that recurrence 
of disease and misuse of medication can be avoided.  In this 
day and age, where vaginal and sexually transmitted diseases 
are exponentially increasing due to our ‘boundary-less’ way of 
living, the author strongly believes that prevention, especially 
through ‘out there’ education, should be given more importance 
and validity. The path to achieving a balance is simple… the 
difficulty lies in choosing it.   
references
1. Khan Shazia A et al. evaluation of Common organisms causing Vaginal 
Discharge.  J Ayub Med Coll Abbottabad 2009; 21(2):90-3.
2. eckert Linda o. Acute Vulvovaginitis.  The New england Journal of 
Medicine 2006; 1244- 1252.
3. Verstraelen, H.  Cutting edge: the vaginal microflora and bacterial 
vaginosis.  Verh K Acad Geneeskd Belg 2008; 70(3):147-74.
4. Hill GB, eschenbach DA, Holmes KK. Bacteriology of the Vagina. 
Scand J urol Nephrol Suppl. 1984;86:23-39.
5. Martin R, Soberon N, escobedo S, Suarez Je. Bacteriophage 
induction versus vaginal homeostasis: role of H2o2 in the selection of 
Lactobacillus defective prophages.  Internation Microbiology 2009; 
12:131-6. 
Adverse events should be reported. Report adverse events to E.J. Busuttil Ltd. Tel: +356 21 44 7184
OAB: It’s time to think 
of something else.
The ﬁrst ß3-adr
enoceptor agon
ist  
to treat overact
ive bladder
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Presentation: Betmiga™ 
prolonged release tablets 
containing 25 mgor 50 mg 
mirabegron. Indication: Symptomatic treatment of urgency, 
increased micturition frequency and/or urgency 
incontinence as may occur in adult patients with overactive 
bladder (OAB) syndrome. Dosage: Adults (including the 
elderly): Recommended dose: 50 mg once daily. Children 
and adolescents: Should not be used. Contraindications: 
Hypersensitivity to active substance or any of the excipients. 
Warnings and Precautions: Should not be used in 
patients with end stage renal disease, severe hepatic 
impairment and severe uncontrolled hypertension. Not 
recommended in patients with severe renal impairment and 
moderate hepatic impairment concomitantly receiving 
strong CYP3A inhibitors. Dose adjustment to 25 mg is 
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QT prolongation or in patients taking medicines known to 
prolong the QT interval. Not recommended during 
pregnancy and in women of childbearing potential not using 
contraception. Not recommended during breastfeeding. 
Interactions: Clinically relevant drug interactions between 
Betmiga™ and medicinal products that inhibit, induce or are 
a substrate for one of the CYP isozymes or transporters 
are not expected, except for inhibitory effect on the 
metabolism of CYP2D6 substrates. Betmiga™ is a moderate 
and time-dependant inhibitor of CYP2D6 and weak 
inhibitor of CYP3A. No dose adjustment needed when 
administered with CYP2D6 inhibitors or CYP2D6 poor 
metabolisers. Caution if co-administered with medicines 
with a narrow therapeutic index and significantly 
metabolised by CYP2D6. When initiating in combination with 
digoxin the lowest dose for digoxin should be prescribed and 
serum digoxin should be monitored. Adverse Effects: 
Urinary tract infection, tachycardia, palpitation, atrial 
fibrillation, blood pressure increase, leukocytoclastic vasculitis. 
Prescribers should consult the Summary of Product 
Characteristics in relation to other side effects. Pack and 
Prices: Country specific. Legal Category: POM. Product 
Licence Number: Betmiga™ 25 mg EU/1/12/809/003; 
Betmiga™ 50 mg EU/1/12/809/010. Date of Preparation: 
November 2012 Further information available from: 
Astellas Pharma Europe B.V. P.O. Box 344, 2300 AH Leiden, The 
Netherlands. Betmiga™ is a Registered Trademark. For full 
prescribing information please refer to the Summary of 
Product Characteristics. 20140312-UR-BTMA-08
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We are seeking to recruit a full-time/part-time/afternoons-only Pharmacist to 
work in an established community pharmacy operated by Collis Williams Ltd.
Applicants must have an E-ID and working knowledge of the POYC system, 
good managerial and communication skills, show self-motivation and an energetic 
approach, together with excellent interapersonal skills and a smart disposition. 
Conditions and remuneration are negotiable and commensurate with experience.
Interested individuals please send an updated CV and covering letter on  
info@colliswilliams.com and maxbm@colliswilliams.com.  
All applications will be treated in the strictest confidence.
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